Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Integer Announces CEO Succession Plan | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Integer Announces CEO Succession Plan

Payman Khales is appointed CEO as Joseph Dziedzic will retire.

By: Rachel Klemovitch

Assistant Editor

Integer Holdings Corporation, a medical device contract development and manufacturing organization, announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. 

Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the company’s Board of Directors. For a smooth transition, Dziedzic will serve as an advisor to the company through March 31, 2026.

“We are incredibly grateful to Joe, whose vision, strategy, and ability to create a high-performance culture has driven Integer’s significant growth and value creation during his eight-year tenure as CEO,” said Pamela G. Bailey, Chair of the Board. “Among many other accomplishments, Joe reshaped Integer’s business to focus on high-growth markets that address unmet patient needs, accelerated organic and inorganic investment in differentiated technologies, and developed and implemented the Integer Production System to create consistency across our manufacturing operations.”

Khales joined Integer in 2018 as President of the Cardio & Vascular business. Under his leadership, the business established a successful market/customer-based strategy, doubling sales in seven years, accelerating market penetration, and achieving above-market growth. 

Since becoming COO, he has overseen both of Integer’s business units, Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation, along with global operations and manufacturing strategy.

Dziedzic said, “Payman is the natural choice to guide Integer through our next chapter of growth. He is an exceptional leader who embodies our commitment to innovation, quality, and operational excellence, and his track record speaks for itself. Payman has been an integral part of the development and execution of our strategy, both within Cardio & Vascular and across the enterprise, while leading Integer’s Customer Operational Strategic Imperatives.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters